News Sentiment

CNTB sentiment intelligence

Connect Biopharma Holdings Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 61 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.38 Week of 17 Jul 2026
Weighted tone 61/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

73/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-5.2% over one week, +19.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Lake Street Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $9

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 73/100 classification
One-week reaction -5.2% Price reacting lower
Trend fit Trend inactive 19.0% over four weeks
Fair value 2.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 31
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Stock Titan 7
Investing.com 5
GlobeNewswire 5
Moomoo 4
TradingKey 4
marketscreener.com 3
TradingView 3

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 15
Analyst action 11
Balance sheet 4
Guidance 4
Capital return 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Stock Titan Direct company coverage

Connect Biopharma finishes asthma study enrollment, data due in September

Connect Biopharma has completed enrollment for its Phase 2 Seabreeze STAT Asthma study, which evaluates rademikibart for acute asthma exacerbations, and expects topline data in early September 2026. The company also anticipates completing enrollment for a related COPD study this

Tone
Positive 66/100
Event
Guidance
Published
17 Jun 2026 13:10
Source
Stock Titan
Stock Titan Direct company coverage

Director-linked fund boosts Connect Biopharma (NASDAQ: CNTB) stake

An entity linked to Connect Biopharma director James Huang, Panacea Venture Healthcare Fund II, L.P., purchased 150,000 Ordinary Shares of Connect Biopharma (NASDAQ: CNTB) at a weighted average price of $2.4774 per share. This transaction increases the fund's indirect holdings to

Tone
Positive 71/100
Event
Deals and strategy
Published
02 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

[EFFECT] Connect Biopharma Holdings Ltd SEC Filing

Connect Biopharma Holdings Ltd (NASDAQ: CNTB) announced that its F-3 shelf registration statement became effective on June 1, 2026, at 4:00 PM. The filing, dated June 2, 2026, specifies the company's CIK as 0001835268 and file number 333-295921. This indicates the company can off

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 10:09
Source
Stock Titan
Simply Wall Street Direct company coverage

Connect Biopharma Holdings (NasdaqGM:CNTB) Stock Forecast & Analyst Predictions

Connect Biopharma Holdings (CNTB) is projected for significant growth, with earnings forecast to increase by 2.2% and revenue by 52.7% per annum. The company's lead product, rademikibart, has shown promising results in clinical trials for atopic dermatitis, asthma, and COPD, with

Tone
Positive 61/100
Event
Earnings
Published
26 May 2026 21:39
Source
Simply Wall Street
Moomoo Direct company coverage

Canaccord Genuity Initiates Connect Biopharma at Buy With $6 Price Target

Canaccord Genuity has initiated coverage on Connect Biopharma (NASDAQ: CNTB) with a Buy rating and a price target of $6. The firm's positive outlook suggests confidence in the biopharmaceutical company's future performance and potential for stock appreciation.

Tone
Positive 77/100
Event
Analyst action
Published
26 May 2026 19:09
Source
Moomoo
TradingView Direct company coverage

Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026

Connect Biopharma's CEO, Barry Quart, highlighted the differentiated clinical profile of their rademikibart program, an IL-4 receptor alpha monoclonal antibody, as the company anticipates SEABREEZE study data in mid-2026. Quart discussed the drug's abilities to lower eosinophils

Tone
Positive 73/100
Event
Market update
Published
25 May 2026 09:09
Source
TradingView